DF/HCC Program Affiliation

Lung Cancer, Co-Leader
Translational Pharmacology and Early Therapeutic Trials

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

Lung cancer is the leading cause of death from cancer in the United States. Better understanding of oncogenes and tumor suppressor genes involved in lung cancer hold the promise of improving clinical care of afflicted patients.

Prior work from our group has focused on transcription factors involved in lung cancer and mechanisms of sensitivity/resistance of oncogene kinases (such as EGFR, ALK, KRAS) to tyrosine kinase inhibitors in non-small-cell lung cancer.

Our group is also part of the clinical research effort at DFHCC, with a focus in non-small-cell lung cancer. We are part of the NIH/NCI-funded SPORE in Lung Cancer at DFHCC.

(co-investigators: Daniel G. Tenen, MD, Mark Huberman, MD and Susumu Kobayashi, MD, PhD)

Publications

View All Publications